STUDboardsPlay · Research · Self · Fit · Money · Learn · Study · Plan · Token STUDtokenOptional

STUDresearch · Peptide

VK2735

Also known as

Viking VK2735 · VK-2735 · VKTX dual agonist · Viking GLP-1/GIP dual agonist · VENTURE VK2735 · VANQUISH VK2735 · Oral VK2735 / VK2735 tablet

Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.

Open in the directory ↗
Peptide Niche talk Systemic SubQ / oral Metabolic / GLP-1 class

Systemic — dual GLP-1/GIP agonist developed as weekly SubQ and daily oral formulations for whole-body metabolic effects.

What people say VK2735 is Viking Therapeutics' investigational dual GLP-1/GIP agonist in weekly SubQ and daily oral development. It is not approved, not tirzepatide, and gray-market products are not clinical supply. Doses people talk about
Phase 2 weekly SubQ arms2.5, 5, 10 or 15 mg once weekly

Thirteen-week VENTURE groups in adults with obesity or overweight plus a comorbidity.

Phase 3 weekly SubQ targets7.5, 12.5 or 17.5 mg once weekly

Investigational VANQUISH target-dose arms versus placebo across 78 weeks.

Phase 2 daily oral arms15, 30, 60, 90 or 120 mg once daily

Thirteen-week VENTURE-Oral tablet groups; several higher-dose arms used protocol titration.

These rows describe randomized study groups, not an approved product label or a home titration plan. The program remains investigational.

Half-life & effect duration

Half-life in the body
  • Under-the-skin injectionAbout 170–250 hours — roughly 7–10 days
Felt duration people report
  • Trial observationsDigestive effects early in treatment; weight changes over weeks
  • After one doseNo consistent firsthand felt window reported
Timing context & sources
How it may feel Human evidence is trial-based, not a rich consumer diary set. Nausea, vomiting, constipation and diarrhea clustered early or after step-ups, while weight changed across weeks; those endpoints do not define a per-dose subjective window.
Cycles people discuss The development model is chronic obesity treatment: 13-week Phase 2 studies and 78-week Phase 3 weekly SubQ trials. Less-frequent maintenance arms remain investigational, not a community on/off cycle. Timing Current trials schedule SubQ VK2735 once weekly and oral VK2735 once daily; higher-dose arms use protocol step-ups, and the maintenance study also tests less-frequent experimental schedules. These controlled trial calendars for an unapproved drug are not interchangeable self-use timing. Stacks Trials study VK2735 with diet and activity counseling. Tirzepatide, semaglutide, retatrutide and oral competitors are comparisons, not established co-stacks; sequential oral/SubQ maintenance research uses the same molecule. Watch for GI class effects (core): Nausea, vomiting, constipation, diarrhea, and abdominal discomfort dominate — mostly mild/moderate in trial tables, early after start or step-ups, often declining with continued dosing.
Related
TirzepatideSemaglutideRetatrutideOrforglipron

Tap a line to jump into the full notes. Research only — may be wrong.

Timing context & sources

Half-life in the body

Single-dose SubQ VK2735 half-life was approximately 170–250 hours.

The sponsor reports Tmax of about 75–90 hours in the same Phase 1 SAD program, supporting once-weekly SubQ development.

Sponsor-reported early-phase result; not an oral half-life, not every repeated dose or population, and not a subjective-effect duration.

Felt duration people report

No per-dose subjective appetite, satiety or nausea duration is established from the inspected evidence.

Trials report front-loaded GI adverse events and progressive multi-week weight change; community discussion is mostly interpretation of study tables rather than verified self-use diaries.

Adverse-event incidence and group weight curves do not supply an individual felt-duration clock; the product remains investigational.

Other context in this card

What people say 16

  • SC Phase 2 weight loss (VENTURE, 13 weeks weekly SC): Mean reductions ~9.1% (2.5 mg), ~10.9% (5 mg), ~12.9% (10 mg), ~14.7% (15 mg) vs ~1.7% placebo; absolute loss roughly ~9.2 kg lowest to ~14.6 kg highest dose. trial
  • SC placebo-adjusted: Up to ~13.1% mean placebo-adjusted loss at 15 mg / week 13. trial
  • SC responders (≥5%): ~93% of active-treated participants (130/140) vs ~12% placebo; per-dose ≥5% rates from ~81% at 2.5 mg to ~100% at 15 mg in published summaries. trial
  • SC responders (≥10%): Dose-responsive; up to ~88% at 15 mg vs ~4% placebo; ≥15% rates highest at 10–15 mg. trial
  • Early SC signal: Statistically significant weight difference vs baseline and placebo from week 1 at all SC Phase 2 doses; progressive loss with no plateau by week 13. trial
  • Post-last-SC-dose hold: PK subset maintained majority of lost weight 4 weeks after final dose (lowest 2.5 mg arm held ~98% of initial loss at 4 weeks); combined PK subset held >80% at ~7 weeks post-last dose — fuels monthly-maintenance research interest. trial
  • Oral placebo-adjusted: Up to ~−10.9% at 120 mg vs placebo at 13 weeks; doses >15 mg separated from placebo from week 1 onward with no plateau at week 13. trial
  • Oral responders: Up to ~97% ≥5% weight loss on active vs ~10% placebo; up to ~80% ≥10% vs ~5% placebo (highest oral arms). trial
  • Oral low-dose maintenance POC: Exploratory arm rapidly titrated to 90 mg daily, then down-titrated to 30 mg daily for 7 weeks — weight loss held (~−9.2% at week 13; progressive through high-dose then maintained on 30 mg). Sponsor discussion also notes maintenance may work at doses <30 mg. trial
  • Oral Phase 1 MAD (28 days): Dose-dependent loss up to ~5.3% early cohorts and later up to ~8.2% from baseline at higher 60–100 mg daily cohorts; up to ~100% of some high-dose cohorts hit ≥5% at day 28 vs 0% placebo in updated ObesityWeek summaries. trial
  • Oral Phase 1 post-dose lag: Weight reductions often maintained or improved days after last oral dose (e.g. day 34 / follow-up through ~day 57 in higher-dose updates) — consistent with lasting pharmacodynamic effect beyond single-day plasma peak. trial
  • SC Phase 1 MAD (up to 28 days): Mean weight loss up to ~18 lb from baseline in healthy obese volunteers; established PK half-life and tolerability before VENTURE. trial
  • Class appetite effect: Dual-agonist framing expects strong satiety / lower food intake; true consumer “VK2735 diary” volume remains thin vs tirzepatide/semaglutide — most “benefits” quotes still come from trial tables. forum
  • Cross-trial context (not head-to-head): Sponsor and secondary reviews note VENTURE 13-week SC losses comparing favorably to historical ~6% semaglutide / ~8% tirzepatide at ~12 weeks in other programs — cross-trial only, different populations and designs. trial
  • Cardiometabolic population fit: Oral Phase 2 population framed as practice-like (mean BMI ~37, age ~51, high prediabetes prevalence ~54%) — efficacy talk includes real-world comorbidity mix, not only lean research subjects. trial
  • Oral Phase 2 weight loss (VENTURE-Oral, 13 weeks once daily tablet): Mean % change ~−2.3% (15 mg), −7.0% (30 mg), −8.7% (60 mg), −11.1% (90 mg), −12.2% (120 mg) vs −1.3% placebo; top arm ~12.1 kg / ~26.6 lb framing in sponsor press. trial

Doses people talk about 16

  • Vs tirzepatide mg: Do not map VK2735 2.5–15 mg SC 1:1 onto tirzepatide 2.5–15 mg pens — different molecules, different exposure curves, different programs. forum
  • Gray-market “VK2735” vials/caps: Any research-chem mg label is unproven identity/purity; trial numbers cannot be copied as a safe DIY recipe. forum
  • Community reality check: Unlike retatrutide/tirzepatide, there is not yet a large forum dose-ladder culture with verified logs — most “dosing talk” is reading Viking tables, not self-reported titration diaries. forum
  • Oral Phase 1 MAD range: Once-daily cohorts from ~2.5 mg up through 100 mg for 28 days with stepped titration (e.g. 100 mg path via 80 mg × 1 wk then 100 mg × 3 wk in disclosed schemes). trial
  • Oral Phase 1 every-other-day exploratory: Subjects titrated to 80 mg daily then switched to 80 mg every other day days 15–28 still showed ~−4.0% mean body-weight change at day 28 — supports lower-frequency oral maintenance hypotheses. trial
  • Maintenance study design (Phase 1-style flexible regimen trial): ~19 weeks weekly SC induction (drug or placebo), then transition to weekly SC, every-other-week SC, monthly SC, daily oral, weekly oral, or placebo — safety/PK/tolerability focus. The current sponsor page says enrollment is complete; the July 29, 2026 update identifies the program as Phase 1 and still framed data as expected in 3Q26. trial
  • Frequency summary: Core obesity efficacy so far = weekly SC or daily oral; monthly SC and weekly oral are research maintenance concepts, not proven community standards. trial
  • SC vs oral mg are not interchangeable: Oral daily doses are tens of mg (15–120); SC weekly doses are single-digit to low teens mg — route, bioavailability, and formulation differ completely. trial
  • SC Phase 2 VENTURE weekly maintenance arms: 2.5 mg, 5 mg, 10 mg, and 15 mg subcutaneous once weekly for 13 weeks (n≈176; obese or overweight with comorbidity). trial
  • SC Phase 2 titration (sponsor notes): 2.5 mg cohort = 2.5 mg × 13 weeks; 5 mg cohort = 2.5 mg × 3 weeks then 5 mg × 10 weeks; higher arms stepped to 10 mg and 15 mg (15 mg arm started titration at 5 mg rather than 2.5 mg). Exact week-by-week kit maps are protocol figures. trial
  • SC Phase 3 VANQUISH weekly arms: 7.5 mg, 12.5 mg, and 17.5 mg once weekly vs placebo for 78 weeks — note these maintenance targets sit near/above the Phase 2 10–15 mg band and include a higher 17.5 mg arm. trial
  • SC Phase 3 program split: VANQUISH-1 ~obesity (~4,500 target enrollment); VANQUISH-2 ~obesity + type 2 diabetes (~1,100 target) — same weekly SC dose set. trial
  • Oral Phase 2 VENTURE-Oral daily arms: 15, 30, 60, 90, and 120 mg once-daily tablet vs placebo for 13 weeks (n=280). trial
  • Oral Phase 2 titration (exact sponsor schedule): 15 mg = 15 mg × 13 wk; 30 mg = 30 mg × 13 wk; 60 mg = 30 mg × 2 wk → 60 mg × 11 wk; 90 mg = 30 mg × 2 wk → 60 mg × 2 wk → 90 mg × 9 wk; 120 mg = 30 mg × 2 wk → 60 mg × 2 wk → 90 mg × 2 wk → 120 mg × 7 wk. trial
  • Oral maintenance exploratory (Phase 2): 30 mg × 1 wk → 60 mg × 1 wk → 90 mg × 4 wk → 30 mg × 7 wk; weight held after down-titration (~−9.2% week 13). trial
  • Framing: Sponsor trial arms, published Phase 2 schedules, and pipeline discussion only — research/educational context, not advice, not approved labeling, not a home protocol. trial

How it may feel 8

  • Oral GI reputation debate: Oral Phase 2 met efficacy endpoints but high-dose vomiting (~35% at 90–120 mg) and early discontinuations (up to ~38% at 120 mg) drove investor/community “mixed” tolerability talk despite mostly mild/moderate labeling. forum
  • Days 1–7 (SC): GI side effects — especially nausea — cluster early; weekly nausea rate in VENTURE SC did not exceed ~5% after the first week across combined arms once titration settled. trial
  • Days 1–7 (oral Phase 2): GI events also front-loaded; weekly rates of nausea or vomiting did not exceed ~5% after the third week of treatment across combined oral arms. trial
  • Weeks 1–4: Progressive scale change on weekly SC or daily oral; appetite drop typically precedes largest cumulative % loss. trial
  • Weeks 4–13 (both formulations): Weight curves still falling at week 13 with no plateau in Phase 2 SC or oral programs — community takeaway is “13 weeks is early runway, not ceiling.” trial
  • Titration flare pattern: Each step-up can re-ignite nausea/vomiting; trials used stepwise escalation for that reason. The SC 15 mg arm that started at 5 mg (not 2.5 mg) had the highest first-week nausea — informs “start low” Phase 3 design talk. trial
  • After last SC dose: Multi-week residual weight hold in PK follow-up (4 and 7 weeks) — not proof of permanent loss without ongoing therapy, but supports spaced maintenance research. trial
  • Months 3–18+ (Phase 3 horizon): VANQUISH uses ~78 weeks of weekly SC — clinical model is chronic obesity therapy, not a short cut cycle. Real-world multi-month “VK2735” user logs remain sparse. trial

Cycles people discuss 8

  • Forum vs care language: Forums may say “cycles”; obesity trial care talks continuous titration, hold at lowest effective dose, and re-escalation if regain — not timed on/off PED cycles. forum
  • Restart after gap: Class/community logic is re-titrate from a low step rather than jumping back to prior high dose when GI sensitivity returns — no approved VK2735 patient label yet. forum
  • Clinical model: Chronic continuous dual-agonist therapy for obesity — multi-month to multi-year horizon — not a 4–8 week bodybuilding “blast.” trial
  • Phase 2 SC block: ~13 weeks active weekly dosing after abbreviated titration, plus ~6-week safety follow-up in VENTURE design (~23 weeks total study calendar including screening). trial
  • Phase 2 oral block: ~13 weeks once-daily tablet with defined step-ups; exploratory maintenance down-titration nested inside the same window. trial
  • Phase 3 SC window: ~78 weeks weekly injection (VANQUISH-1/2) — defines the long efficacy/safety bar for registration. trial
  • Induction → maintenance concept: Sponsor narrative: weekly SC (or high oral) for loss, then less-frequent SC (QOW/monthly) or lower/less-frequent oral to hold — same molecule across phases. trial
  • Stop / observe: Substantial weight held weeks after last SC dose in Phase 2 follow-up; long-term regain after permanent stop is not yet fully characterized for VK2735 specifically but is class-expected. trial

Timing 8

  • Washout expectation: After last SC dose, multi-week residual drug and residual weight effect are expected; full clearance and appetite return timelines are individual and not fully mapped in consumer data. forum
  • SC half-life (Phase 1 SAD): Approximately 170–250 hours after single subcutaneous doses — multi-day elimination supporting weekly (and potentially less frequent) dosing. trial
  • SC Tmax: Peak plasma ~75–90 hours post-SC injection. trial
  • Why weekly SC: Long half-life and VENTURE/VANQUISH once-weekly protocols align; fatty-acid conjugation / albumin binding is the disclosed half-life-extension strategy. trial
  • Monthly SC hypothesis: Post-dose weight hold + measurable residual exposure after last weekly dose underpin sponsor interest in once-monthly maintenance SC — still experimental (maintenance study). trial
  • Oral schedule: Phase 2 efficacy = once daily tablet; Phase 1 also explored every-other-day oral after high-dose induction. Weekly oral is a maintenance-study arm, not a Phase 2 efficacy standard. trial
  • Weight vs plasma lag: Scale change continues across 13 weeks and can lag after the last dose — satiety/weight effects are not limited to the Tmax hour. trial
  • Oral vs SC exposure: Different routes produce different absolute mg and exposure; “same molecule” does not mean same bioavailability or same weekly AUC at equal printed mg. trial

More on what it is 8

  • Not the same as: Tirzepatide (Lilly dual GIP/GLP-1, approved), semaglutide (GLP-1 only), retatrutide (triple GIP/GLP-1/glucagon), orforglipron (oral small-molecule GLP-1 only), or unlabeled “dual agonist” powders. forum
  • Research lens: Trial mg figures, % weight loss, and titration schedules are clinical context — not self-experiment protocols, medical advice, or proof that gray-market “VK2735” matches clinical lots. forum
  • What it is: Viking Therapeutics (VKTX) investigational dual agonist of the GLP-1 and GIP receptors — one peptide molecule developed in both once-weekly subcutaneous and once-daily oral tablet formulations. trial
  • Why people care: Tirzepatide-class dual pharmacology with dense Phase 1–2 human data (SC VENTURE up to ~14.7% at 13 weeks; oral VENTURE-Oral up to ~12.2% at 13 weeks) and an ongoing Phase 3 VANQUISH program — denser evidence than most gray-market “research peptides.” trial
  • Mechanism talk: GLP-1 + GIP co-agonism framed as stronger appetite and metabolic effect than GLP-1 alone; fatty-acid side chain extends SC half-life into the multi-day range that supports weekly dosing. trial
  • Same-molecule dual route: Sponsor differentiator vs many peers — injectable and oral use the same active dual agonist, which is discussed as a way to induce on SC then maintain on oral (or reverse) without switching compounds. trial
  • Evidence level: Phase 1 SAD/MAD SC and oral MAD; Phase 2 SC VENTURE (published Obesity journal); Phase 2 VENTURE-Oral tablet; Phase 3 VANQUISH-1/2 weekly SC; separate maintenance-dosing study (weekly / QOW / monthly SC and daily / weekly oral arms). trial
  • Status: Not FDA-approved as of last research; not a generic or compounded tirzepatide equivalent; not a verified consumer research-chem staple with rich self-experiment logs. trial

Stacks 7

  • Comparisons, not co-stacks: Discussion sits next to tirzepatide, semaglutide, retatrutide, CagriSema, amycretin, survodutide, orforglipron — usually as alternatives, not simultaneous injectables. forum
  • Do not dual-stack incretins: Combining VK2735-class dual agonism with another GLP-1/GIP/glucagon agent multiplies GI risk; no home “VK + tirz” trial exists. forum
  • Protein / resistance training (class community): Standard incretin talk to protect lean mass during large absolute loss — not VK2735-specific RCTs. forum
  • Anti-nausea adjuncts (class talk): Clinics/forums sometimes discuss temporary antiemetics or slower titration for GLP-1/GIP GI — not a Viking-endorsed stack protocol. forum
  • Monotherapy frame: Obesity dual-agonist programs study VK2735 alone plus diet/activity counseling — not BPC-157/TB-500 injury stacks. trial
  • Lifestyle co-factors: Reduced-calorie diet and increased activity are built into trial contexts and drive outcomes beyond drug % alone. trial
  • Same-molecule SC↔oral transition: The intended “stack” in sponsor narrative is sequential route flexibility (induce SC → maintain oral, or oral induction concepts), not two different agonists at once. trial

Storage notes 2

  • No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
  • Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum

Watch for 19

  • Heart rate / other class effects: Dual agonists as a class can raise resting pulse modestly; VK2735-specific long-horizon HR summaries should be taken from primary Phase 3 outputs when available rather than assumed identical to tirzepatide. forum
  • Identity / counterfeit risk: Non-clinical “VK2735” powders or vials carry mislabel, contaminant, under-dosing, and legal risk — storage advice is not authenticity. forum
  • Not free or DIY-safe: Strong appetite suppression, GI burden, and nutrition risk (under-protein, dehydration) mean research interest ≠ safe unsupervised use. forum
  • Stock-headline ≠ body outcome: Market reactions to oral tolerability do not change individual biology but do shape community confidence; efficacy and dropout rates should both be read from tables. forum
  • GI class effects (core): Nausea, vomiting, constipation, diarrhea, and abdominal discomfort dominate — mostly mild/moderate in trial tables, early after start or step-ups, often declining with continued dosing. trial
  • SC VENTURE nausea: ~43% on VK2735 vs ~20% placebo; among active, ~68% of nausea mild / ~32% moderate / none severe in sponsor summaries. trial
  • SC VENTURE vomiting: ~18% (25/140) on active vs ~0% on placebo. trial
  • SC VENTURE other GI: Constipation ~26% vs ~11% placebo; diarrhea ~20% vs ~9% placebo. trial
  • SC discontinuation: Overall treatment discontinuations ~13% active vs ~14% placebo — described as low and balanced; one drug-related SAE of dehydration reported in VENTURE SC. trial
  • SC TEAE severity: ~92% of drug-related TEAEs mild or moderate; ~95% of GI TEAEs mild or moderate. trial
  • SC start-dose lesson: 15 mg arm starting at 5 mg (not 2.5 mg) had highest week-1 nausea — supports Phase 3 preference for lower starts and slower titration. trial
  • Oral Phase 2 nausea: ~58% active vs ~48% placebo (high placebo GI also noted in commentary); vast majority mild/moderate (~99%). trial
  • Oral Phase 2 vomiting: ~26% active vs ~10% placebo; ~35% at each of the 90 mg and 120 mg arms in safety tables. trial
  • Oral Phase 2 other GI (examples): Diarrhea up to ~25% at 120 mg; constipation up to ~43% at 90 mg in disclosed tables; abdominal pain generally low single digits. trial
  • Oral discontinuation: AE-related discontinuation ~20% active vs ~13% placebo; overall early treatment stop ~28% active vs ~18% placebo; highest at 120 mg (~38% discontinued treatment early). trial
  • Oral Phase 1 contrast: Early 28-day oral MAD reported milder GI (e.g. mild nausea ~14–32% depending on data cut; vomiting rare/none in early cuts) before longer Phase 2 exposure and higher-dose arms. trial
  • Titration matters: Fast jumps worsen early GI; both SC and oral programs used stepwise escalation — “load high day one” is not the studied pattern. trial
  • Class unknowns still open for VK2735 specifically: Long-term rare risks (gallbladder events, pancreatitis signals, lean-mass fraction, retinopathy in susceptible patients, medullary thyroid C-cell class warnings on related approved agents) need Phase 3 duration and post-marketing-style follow-up; do not assume zero class risk because a dual agonist is “new.” trial
  • Pregnancy / special populations: Obesity trials enroll defined adult BMI populations; pregnancy, pediatric, and many comorbidity groups are outside routine discussion — class incretins have standard clinical cautions. trial

Updated: 2026-08-12

Evidence mix More trial/lab tags than forum tags Full: every bullet (trial + community). Use Scan for a faster bro-science read.
↑ Back to top

All STUDresearch topics →